← Back to all trials
Recruiting
NCT07226427
A First-in-Human Study of MEN2501 in Participants With Platinum-Resistant Ovarian Cancer
Conditions: Platinum-resistant Ovarian Cancer
Sex: Female
Ages: 18 Years – N/A
Healthy volunteers: No
Phase: PHASE1
Enrollment: 100
Sponsor: Stemline Therapeutics, Inc.
Location: Highlands Oncology Group Springdale Arkansas
Summary
This is a first-in-human, open-label, dose-escalation, dose-optimization trial designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and antitumor activity of MEN2501 monotherapy in adult participants with platinum-resistant ovarian cancer.
Eligibility Criteria
Key Inclusion Criteria:
* Participants must have a histopathologically confirmed diagnosis of high-grade serous ovarian cancer, primary peritoneal cancer, or fallopian tube cancer.
Key Exclusion Criteria:
* Participants with primary platinum-refractory disease.
Note: Other protocol-defined inclusion/exclusion criteria may apply.
Source: ClinicalTrials.gov (NCT07226427). StuddyBuddy aggregates publicly available trial information.
